Who is sponsoring NCT05605470?

NCT05605470 is sponsored by Technovalia, Pty Ltd.

What drugs are being tested in NCT05605470?

Interventions in NCT05605470: ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg).

What condition does NCT05605470 study?

NCT05605470 studies COVID-19, SARS CoV 2 Infection.

Is NCT05605470 still recruiting?

NCT05605470 is currently completed. Last updated 13 April 2025.

Last reviewed 2025-04-13 · How we verify

NCT05605470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

Completed Phase 2 Last updated 13 April 2025

What this trial tests

Phase 2 trial testing ChulaCov19 BNA159 vaccine (50 mcg) in COVID-19, SARS CoV 2 Infection in 150 participants. Completed in 18 November 2024.

Timeline

19 January 2023

Primary endpoint
15 July 2024

18 November 2024

Quick facts

Lead sponsor	Technovalia, Pty Ltd
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	150
Start date	19 January 2023
Primary completion	15 July 2024
Estimated completion	18 November 2024
Sites	5 locations across Australia

Drugs / interventions tested

ChulaCov19 BNA159 vaccine (50 mcg) — full drug profile →
Pfizer/BNT vaccine (30 mcg) — full drug profile →
COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg) — full drug profile →

Conditions studied

COVID-19, SARS CoV 2 Infection — all drugs for COVID-19, SARS CoV 2 Infection →

Sponsor

Technovalia, Pty Ltd — full company profile →

Who can join

Adults 18 to 64, any sex, with COVID-19, SARS CoV 2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous booster dose of any authorized/approved COVID-19 vaccine.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice.
Prompetchara E, Ketloy C, Alameh MG, Tharakhet K, et al · · 2023 · cited 23× · PMID 37085495 · DOI 10.1038/s41467-023-37795-0
Research progress of mRNA vaccines for infectious diseases.
Zhang Z, Du J, Zhang D, Han R, et al · · 2025 · cited 5× · PMID 40847375 · DOI 10.1186/s40001-025-03060-x
Comparative analysis of the effectiveness difference of SARS-COV-2 mRNA vaccine in different populations in the real world: A review.
Cai S, Chang C, Zhang X, Qiao W. · · 2023 · cited 4× · PMID 37653835 · DOI 10.1097/md.0000000000034805

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05605470 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technovalia, Pty Ltd
Last refreshed: 13 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing